Obstetrics & Gynaecology
Premenstrual Syndrome (GTG 48)
Premenstrual Syndrome (GTG 48) clinical pathway.
Source: RCOG; NAPS — RCOG GTG 48 (2017)
Step 1 of ~4
info
Diagnosis & Assessment
Definition: Distressing physical, behavioural, psychological symptoms in luteal phase, absent post-menses
Diagnosis: Prospective symptom diary for ≥2 cycles (essential)
Severity:
• Mild: Some interference
• Moderate: Function maintained
• Severe: Unable to function/interact
Symptoms:
psychological: Depressed mood, Mood swings, Anxiety, Irritability, Loss of confidence
physical: Bloating, Breast pain, Headaches, Weight gain
behavioural: Reduced cognitive ability, Aggression, Social withdrawal
Symptoms:
Psychological: Depressed mood, Mood swings, Anxiety, Irritability, Loss of confidence
Physical: Bloating, Breast pain, Headaches, Weight gain
Behavioural: Reduced cognitive ability, Aggression, Social withdrawal
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Methylene Blue · Guanylate Cyclase / Nitric Oxide Pathway Inhibitor
- Aciclovir 800mg Tablets (Ramsay Hunt Syndrome / Herpes Zoster Oticus) · Antiviral — nucleoside analogue (herpes zoster treatment)
- Sodium phenylbutyrate · Ammonia scavenger (alternative pathway)
- Pramipexole (Restless Legs Syndrome — Elderly) · Dopamine Agonist (D2/D3 Receptor)
- Marstacimab · Anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody
- Prednisolone (Paediatric) · Corticosteroid — Asthma Exacerbation / Croup / Nephrotic Syndrome / IBD
Decision support only. Always apply local guidelines and clinical judgement.